Literature DB >> 31479527

Obesity and risk of differentiated thyroid cancer: A large-scale case-control study.

Qiao He1, Hui Sun1, Fang Li1, Nan Liang1.   

Abstract

OBJECTIVE: Recently, the incidence of thyroid cancer as well as obesity has dramatically increased worldwide. Whether obesity contributes to the development of differentiated thyroid cancer (DTC) remains controversial. We evaluated the relationship between anthropometric measurements and DTC risk. DESIGN/PATIENTS/MEASUREMENTS: A large frequency-matched case-control study based on hospital data was performed. A total of 10 668 DTC patients and 11 858 controls were enrolled. Body mass index (BMI), body surface area (BSA) and body fat percentage (BF%) were calculated. An unconditional logistic regression model was applied.
RESULTS: The univariate analysis showed a significant increase in DTC risk with increased height, weight, BMI, BSA and BF%. The multivariate analysis also showed a positive relationship. Based on the Chinese BMI (CN-BMI) classification, for women of all ages, the ORs for DTC risk in overweight and obesity were 1.151 (1.037-1277) and 1.292 (1.092-1.528), respectively. For men under 50, the ORs were 1.221 (1.014-1.469) and 1.520 (1.202-1.923), respectively, but the ORs for men over 50 were not significant. Additionally, BSA showed a significant association with DTC risk for both sexes under 50 (P = .02 and P < .001). BF% remained significant only for women under 50 (P = .003). However, for both sexes over 50, neither BSA nor BF% was significantly associated with DTC risk. Based on The World Health Organization BMI (WHO-BMI) classification, for all women and men over 50, the results were consistent with CN-BMI. For men under 50, BF%, but not BMI, showed a significant association with DTC risk.
CONCLUSION: BMI, BSA and BF% were positively correlated with the risk of DTC, which was potentially affected by age and sex.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  anthropometric parameters; case-control study; differentiated thyroid cancer; obesity

Year:  2019        PMID: 31479527     DOI: 10.1111/cen.14091

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Obesity and Waist Circumference are Possible Risk Factors for Thyroid Cancer: Correlation with Different Ultrasonography Criteria.

Authors:  Marwa S Eissa; Mona S Abdellateif; Yasmine F Elesawy; Sabry Shaarawy; Ula M Al-Jarhi
Journal:  Cancer Manag Res       Date:  2020-07-21       Impact factor: 3.989

Review 2.  Adiponectin and Thyroid Cancer: Insight into the Association between Adiponectin and Obesity.

Authors:  Yuanyuan Zhou; Ying Yang; Taicheng Zhou; Bai Li; Zhanjian Wang
Journal:  Aging Dis       Date:  2021-04-01       Impact factor: 6.745

3.  The Ongoing Debate Regarding Completion Thyroidectomy Versus Primary Thyroid Surgery for Low and Intermediate Differentiated Thyroid Carcinoma: A Meta-Analysis.

Authors:  Hyder Mirghani; Ibrahim A Altedlawi Albalawi
Journal:  Cureus       Date:  2020-12-11

4.  Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment.

Authors:  Sara Ahmadi; Theodora Pappa; Alex S Kang; Alexandra K Coleman; Iñigo Landa; Ellen Marqusee; Matthew Kim; Trevor E Angell; Erik K Alexander
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-11       Impact factor: 5.555

5.  Influencing Factors and Cumulative Risk Analysis of Cervical Lymph Node Metastasis of Papillary Thyroid Microcarcinoma.

Authors:  Yirong Yin; Xiang Xu; Liyan Shen; Wenjuan Zhao; Hongcui Diao; Chengqian Li
Journal:  Front Oncol       Date:  2021-09-30       Impact factor: 6.244

Review 6.  The association of obesity with thyroid carcinoma risk.

Authors:  Xiao-Ni Ma; Cheng-Xu Ma; Li-Jie Hou; Song-Bo Fu
Journal:  Cancer Med       Date:  2022-01-15       Impact factor: 4.452

Review 7.  Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.

Authors:  Meng-Ying Cui; Xing Yi; Zhen-Zhen Cao; Dan-Xia Zhu; Jun Wu
Journal:  J Oncol       Date:  2022-09-05       Impact factor: 4.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.